🧔♂️ A friendly human may check it before it goes live. More news here
Living Lab Ventures invests in Indonesian clinical research firm
Living Lab Ventures, the corporate venture capital arm of Sinar Mas Land, has invested in Increase Laboratorium Indonesia, a clinical research company based in BSD City.
Living Lab Ventures said the funding will be used to expand Increase’s operations and strengthen its research capabilities.
Increase provides clinical trial and laboratory services for healthcare clients in Indonesia and the wider region.
Increase is currently working with clients from Indonesia, Singapore, Australia, and China, and has partnered with Tsinghua University and the University of Osaka on research and training initiatives.
The company is seeking international certifications such as CAP and ISO standards to bolster its credibility in the clinical research sector.
Indonesia’s contract research organization market is projected to reach US$1 billion by 2030, according to a report by 6Wresearch.
🔗 Source: Living Lab Ventures
🧠 Food for thought
Implications, context, and why it matters.
Indonesia’s contract research organization (CRO) market growth tracks Southeast Asia clinical trial expansion
- 6Wresearch projects a US$1 billion market by 2030, up from a small base. Rising participation in global trials draws drugmakers seeking diverse patients and lower costs.
- Increase works with Tsinghua University and the University of Osaka. These ties build cross-border know-how that helps local CROs meet international expectations.
- Pursuit of College of American Pathologists (CAP) and International Organization for Standardization (ISO) certifications addresses quality doubts. These badges help win work from multinational pharma where regulatory compliance is non-negotiable.
Life sciences software vendors can target Indonesia’s growing CRO sector as a gateway market
- Vendors of eClinical trial management systems, patient recruitment tools, plus compliance software can find early adopters among Increase and peers. These firms want to scale and clear certification hurdles.
- Work from Singapore, Australia, and China creates demand for interoperable data platforms plus cloud setups that coordinate trials across borders while meeting different data rules.
- Focus on tools for Indonesia’s realities, such as multi-site coordination across an archipelago and digital patient consent, to help local CROs win more multinational work.
Stay updated on the go with our mobile app.
Get latest insights with smoother, more personalized experience through TIA mobile app.